In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vir Biotechnology Inc.

www.vir.bio

Latest From Vir Biotechnology Inc.

Stockwatch: Antibodies And Coronavirus – It’s Complicated

The use of antibodies in disease prevention and treatment is now ingrained in modern medicine but as antiviral agents their record is at best patchy and the reliance on them to treat or prevent coronavirus infections is perhaps premature.

Coronavirus COVID-19 Stockwatch

BIO 2020 Notebook: McMurry-Heath On Restoring Hope, Greenwood On Defeating Climate Skeptics

News and views from day one of  BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change. 

Coronavirus COVID-19 Human Capital

BIO 2020 Notebook: McMurry-Heath On Restoring Hope, Greenwood On Defeating Climate Skeptics

News and views from day one of BIO Digital: Industry leaders discuss speeding up drug development amid COVID-19; new CEO Michelle McMurry-Heath wants to restore hope in populations that feel left behind; and former CEO Jim Greenwood aims to defeat politicians who deny climate change. 

Companies Research & Development

Coronavirus Update: Gilead Ready To Unveil Remdesivir Price

Gilead is preparing to unveil its long-term commercial plan for the antiviral therapy, including its expectations on prices and profits.

Coronavirus COVID-19 Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Vir Biotechnology Inc.
  • Senior Management
  • George Scangos, PhD, CEO
    Howard Horn, CFO
    Phil Pang, MD, PhD, CMO
    Jay Parrish, PhD, CBO
    Herbert Virgin, MD, PhD, EVP, Rsch. & CSO
  • Contact Info
  • Vir Biotechnology Inc.
    499 Illinois, Ste. 500
    San Francisco, CA 94158
    USA
UsernamePublicRestriction

Register